MBX Biosciences, Inc. Common Stock (MBX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.78B
Last updated: Nov 17, 2026 at 11:06 AM ET
MBX Biosciences, Inc. Common Stock (MBX) Stock Forecast
Analysts expect MBX Biosciences, Inc. Common Stock (MBX) to earn -$3.56 per share in the fiscal year ending Dec 31, 2026. Of 11 analysts, 11 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 3 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 11 ratings average 1.73, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 27.3% |
| Buy | 8 | 72.7% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 11
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$3.56
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$4.31
- EPS consensus
- Next report
- Mar 10, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$3.56 | -$3.75 to -$3.41 | 5 |
| Dec 31, 2027 | -$4.31 | -$5.11 to -$3.89 | 8 |
Quarterly Estimates
The EPS consensus is -$0.99 for both quarters below, ending Dec 31, 2026 and Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.99 | -$1.35 to -$0.84 | 12 |
| Mar 31, 2027 | -$0.99 | -$1.10 to -$0.89 | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 1 upward and 10 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 3 |
| Fiscal year ending Dec 31, 2027 | 0 | 5 |
| Quarter ending Mar 31, 2027 | 0 | 2 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$3.11.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$3.56 | -$3.05 | -$3.05 | -$3.11 | -$3.11 | N/A |
| Fiscal year ending Dec 31, 2027 | -$4.31 | -$3.98 | -$3.98 | -$3.96 | -$3.94 | N/A |
| Quarter ending Mar 31, 2027 | -$0.99 | -$0.92 | -$0.92 | -$0.92 | -$0.92 | N/A |
Frequently Asked Questions About MBX
What is the MBX stock forecast?
Consensus analyst estimates put MBX Biosciences, Inc. Common Stock's EPS at -$3.56 for the fiscal year ending Dec 31, 2026. The consensus rating from 11 analysts is Buy.
How do analysts rate MBX stock?
Of 11 analysts covering MBX Biosciences, Inc. Common Stock, 3 rate it Strong Buy, 8 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from MBX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$3.56, with estimates from -$3.75 to -$3.41 from 5 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$4.31, with estimates from -$5.11 to -$3.89 from 8 analysts.
How many analysts cover MBX?
11 analysts rate MBX Biosciences, Inc. Common Stock stock, and 5 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
MBX pages: Overview, Earnings, Forecast, Financials, Competitors